22 May 2013
Keywords: update, biogen, elan, pull, ms, drug, tysabri
Article | 07 March 2005
Biogen Idec of the USA and Ireland-based Elan Corp have voluntarily suspended marketing of their multiple sclerosis drug Tysabri
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 March 2005
7 March 2005
© 2013 thepharmaletter.com